Benjamin Edwards Inc Editas Medicine, Inc. Transaction History

Benjamin Edwards Inc

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 07, 2023	BUY	$8.32 - $13.21 $16 - $26	2 Added 9.09%	24 $0
Q3 2022 Oct 28, 2022	SELL	$12.16 - $19.42 $12 - $19	-1 Reduced 4.35%	22 $0
Q1 2022 May 04, 2022	SELL	$14.08 - $27.63 $2,872 - $5,636	-204 Reduced 89.87%	23 $0
Q4 2021 Feb 07, 2022	SELL	$26.55 - $40.57 $7,141 - $10,913	-269 Reduced 54.23%	227 $6,000
Q3 2021 Nov 02, 2021	SELL	$39.27 - $72.94 $4,751 - $8,825	-121 Reduced 19.61%	496 $20,000
Q2 2021 Aug 11, 2021	SELL	$31.29 - $56.64 $2,315 - $4,191	-74 Reduced 10.71%	617 $35,000
Q1 2021 May 14, 2021	BUY	$39.71 - $90.58 $3,891 - $8,876	98 Added 16.53%	691 $29,000
Q4 2020 Feb 16, 2021	SELL	$27.07 - $84.35 $11,613 - $36,186	-429 Reduced 41.98%	593 $42,000
Q3 2020 Nov 16, 2020	BUY	$28.06 - $37.16 $3,086 - $4,087	110 Added 12.06%	1,022 $29,000
Q2 2020 Aug 14, 2020	SELL	$18.5 - $34.34 $647 - $1,201	-35 Reduced 3.7%	912 $27,000
Q1 2020 May 07, 2020	BUY	$14.88 - $32.78 $580 - $1,278	39 Added 4.3%	947 $19,000
Q4 2019 Feb 06, 2020	SELL	$19.49 - $32.63 $682 - $1,142	-35 Reduced 3.71%	908 $27,000
Q3 2019 Nov 05, 2019	BUY	$22.49 - $26.81 $2,114 - $2,520	94 Added 11.07%	943 $21,000
Q2 2019 Aug 08, 2019	BUY	$20.48 - $27.76 $5,447 - $7,384	266 Added 45.63%	849 $21,000
Q1 2019 May 15, 2019	BUY	$19.43 - $26.41 $11,327 - $15,397	583 New	583 $14,000

249

57.1M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $83.2M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Benjamin Edwards Inc, based on Form 13F filings with the SEC.

Stay updated on Benjamin Edwards Inc with notifications on news.